


Be kind to your patients



● Attention Deficit Hyperactivity Disorder



● Narcolepsy



Rx

PHENIDA

PHENIDA

[Methylphenidate HCl] 10 mg Tablets

Be kind to your patients

When remedial measures alone are insufficient
appropriate education placement is essential and psychosocial intervention is generally necessary

● Attention Deficit Hyperactivity Disorder

Diagnostic Criteria: ADHD may have,

- Chronic history of small attention span
- Distractibility
- Emotional lability
- Impulsivity
- Moderate to severe hyperactivity
- Minor neurological signs and abnormal EEG

● Narcolepsy

Diagnostic Criteria: Narcolepsy may have,

- Sleep attacks during the day despite having a normal amount of sleep at night
- Hallucination after sleep or wake up
- Cataplexy; Sudden physical fall because of loss of muscle-tone
- Sleep paralysis; body paralysed for a few seconds after waking
- Sleep apnea leading to day time sleepiness
- Abuse of sedative drugs & withdrawal from stimulant drugs

Dosage: Adult: 20 to 30mg in 2-3 divided dosage, or as directed by Physician. **Children:** Above Six years of age. Initial 5mg once or twice daily then increase 5-10mg weekly.

Prescribing Information:

Composition: Each tablet contains 10mg Methylphenidate Hydrochloride **Indications:** Attention Deficit Hyperactivity Disorder (ADHD) in children (such as psychorganic syndrome, hyperactive syndrome, attention deficit disorder or minimal brain dysfunction), **Narcolepsy** (The symptoms include drowsiness during the day, untimely sleep and rapid loss of voluntary muscle tone **Contraindications:** Known hypersensitivity or idiosyncrasy to methylphenidate or sympathomimetic amines; tics & tics in the siblings, Tourette's syndrome (in the patient or family history) patients with advanced arteriosclerosis. Symptomatic cardiovascular disease, moderate to severe hypertension (stage II or III), hyperthyroidism, glaucoma, anxiety & tension, agitated states; patients with a history of drug abuse; use during or within 14 days following MAO inhibitor therapy; **Precautions:** Safety and efficacy in children under 6 years of age is not established. Use with caution in patients with bipolar disorder, diabetes mellitus, cardiovascular disease, seizure disorder, insomnia, porphyria or mild hypertension (stage I). Potential for drug dependency exists-avoid abrupt discontinuation in patients who have received for prolonged periods. Stimulant use has been associated with growth suppression. If epileptic attacks occur, methylphenidate should be withdrawn. Methylphenidate may adversely affect the patient's reactions and impair his ability to drive vehicles or operate machinery. **Side effect:** Nervousness, insomnia, loss of appetite, tachy or bradycardia, angina, hyper or hypotension, palpitations, cardiac arrhythmias, headache, dyskinesia, toxic psychosis, dizziness, drowsiness, rash, growth retardation, nausea, vomiting, dryness of mouth, abdominal pain, weight loss, thrombocytopenia, anemia, leucopenia, blurred vision and hypersensitivity reactions. **Pregnancy & Lactation:** Pregnancy risk factor "C". In general methylphenidate should not be used during pregnancy. Since no data is available that whether pass into the breast milk or not therefore, either breast-feeding or treatment of the mother should be discontinued. **Drug Interactions:** Methylphenidate may antagonize the adrenergic blockade of guanethidine and guanadrel and inhibit the antihypertensive effect. Methylphenidate may cause hypertensive effects when used in combination with MAOIs; it is best to avoid this combination. **Dosage:** The dosage must be individually adapted. **Adults:** 20-30 mg daily in two or three doses. **Children:** Above 6 year initially 5mg once or twice daily with gradual increase of 5-10 mg each week, (The daily dosage must not exceed 60mg, in divided doses). Moreover, methylphenidate should be withdrawn from time to time so that the child's condition can be reassessed. **Presentation:** Phenida is available in a blister pack of 3X10's.



“Medicines For All”



Zafa Pharmaceutical Laboratories (Private) Ltd.
L-1/B, Block 22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI - 75950 (PAKISTAN)
Email: zafaph@cyber.net.pk Website: www.zafa.com.pk



ISO 9001:2000